The Clinical Trials Core has been active since the initiation of the U54 and has systematically and progressively advanced by sustaining, improving and extending its basic mission. The Core contributes to 1) patient targeting especially minority and underserved accrual on cancer clinical trials, 2) education of hematology/oncology fellows and 3) research into the issues of the minority and underserved patient with cancer. Overall, the Core has entered large numbers of minority and underserved patients onto clinical trials and given these patients opportunities that are usually not available at fail-safe public hospitals. The Core maintains a complete resource for clinical trials including administrative support, IRB support, data collection and management, patient navigation, research nursing support and secretarial assistance. Prior to U54 support, 6 patients were entered on clinical trials at the NGH. In distinction, over the history of the Core, we have accrued 638 patients to clinical trials of which approximately 50% are minorities (African American and Hispanic). The overall accrual rate is 22% of all patients screened. The accrual rate of patients who had a study available for their disease site and stage and who met eligibility criteria is a remarkatjie 53%. At our site, minority patients are no less likely to consent to clinical trials compared to majority patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA163072-01
Application #
8340443
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Project Start
2011-09-23
Project End
2016-08-31
Budget Start
2011-09-23
Budget End
2012-08-31
Support Year
1
Fiscal Year
2011
Total Cost
$272,947
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Hull, P C; Buchowski, M; Canedo, J R et al. (2018) Childhood obesity prevention cluster randomized trial for Hispanic families: outcomes of the healthy families study. Pediatr Obes 13:686-696
Santos-Barriopedro, Irene; Bosch-Presegué, Laia; Marazuela-Duque, Anna et al. (2018) SIRT6-dependent cysteine monoubiquitination in the PRE-SET domain of Suv39h1 regulates the NF-?B pathway. Nat Commun 9:101
Alotaibi, Dalal; Amara, Suneetha; Johnson, Terrance L et al. (2018) Potential anticancer effect of prostratin through SIK3 inhibition. Oncol Lett 15:3252-3258
Odoh, C; Sanderson, M; Williams, E A et al. (2018) Operationalizing outcome measures of human papillomavirus vaccination among adolescents. Public Health 159:129-132
Yang, Yaohua; Cai, Qiuyin; Shu, Xiao-Ou et al. (2018) Prospective study of oral microbiome and colorectal cancer risk in low-income and African American populations. Int J Cancer :
Hull, Pamela; Emerson, Janice S; Quirk, Meghan E et al. (2017) A Smartphone App for Families With Preschool-Aged Children in a Public Nutrition Program: Prototype Development and Beta-Testing. JMIR Mhealth Uhealth 5:e102
Ho, Meng-Hsuan; Lamont, Richard J; Xie, Hua (2017) Identification of Streptococcus cristatus peptides that repress expression of virulence genes in Porphyromonas gingivalis. Sci Rep 7:1413
Uzhachenko, Roman; Boyd, Kelli; Olivares-Villagomez, Danyvid et al. (2017) Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. Aging (Albany NY) 9:627-649
Brown, Shyretha; Tehrani, Shahin; Whalen, Margaret M (2017) Dibutyltin-induced alterations of interleukin 1beta secretion from human immune cells. J Appl Toxicol 37:181-191
Amara, Suneetha; Tiriveedhi, Venkataswarup (2017) The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci 18:

Showing the most recent 10 out of 94 publications